ArticleContact dermatitis2025
Prevalence and Determinants of Sensitisation to Neomycin in North-Eastern Italy, 1997-2021.
Article in Contact dermatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Epidemiological and Occupational Pattern of Patch-Test Reactions to p-Tert-butylphenol-formaldehyde Resin in North-Eastern Italy, 1997-2021.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergic contact dermatitis (ACD) induced by topical application of neomycin is frequently reported.
objectivesThis multi-center study investigated prevalence and determinants of neomycin sensitisations in 30 629 outpatients from North-eastern Italy during 1997-2021. PATIENTS AND
methodsEuropean baseline and extended Triveneto series were applied on the upper back of patients patch testing for suspected ACD and removed after 48 h.
resultsPrevalence of neomycin sensitisation was 2.29% (=701/30 629), significantly decreasing over time, especially after 2003. Neomycin sensitisation increased with age, especially in female patients older than 60 with leg dermatitis. The majority of patients sensitised to neomycin (74.5%) tested positive also against other haptens, particularly ingredients included in creams and emollients, as lanolin or benzocaine or preservatives as thimerosal or parabens.
conclusionsThe decreasing prevalence of neomycin sensitisation over time likely reflected reduced accessibility and circulation of neomycin in Italy, due to containment of prescriptions and over-the-counter accessibility. Older individuals are typically more likely to be treated by topical medications and antibiotics as neomycin for various conditions, including stasis dermatitis. Since ACD caused by topical medications is relatively easy to miss, comprehensive drug history and patch testing are essential for any patient with suspected sensitisation caused by neomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.